Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
Allogeneic Bone Marrow Transplant From HLA Identical Related Donors for Patients With High Risk Hemoglobinopathies: Hemoglobin SS, Hemoglobin SC, Hemoglobin SB0/+ Thalassemia, or Homozygous B0/+ Thalassemia or Severe Variants of B0/+ Thalassemia
Sponsor: Baylor College of Medicine
Terminated
accrual was slow and sporadic so the study was closed
Other terminated trials from Baylor College of Medicine
Listed as NCT00040469, this PHASE2 trial focuses on Hemoglobinopathy and Sickle Cell Anemia and remains terminated or withdrawn. Sponsored by Baylor College of Medicine, it has been updated 7 times since 2000, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Oct 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Feb 2020 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Aug 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baylor College of Medicine
- Center for Cell and Gene Therapy, Baylor College of Medicine
- The Methodist Hospital Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .